Rare Diseases, Galliccia (Aifa): "Alongside Research and Assistance, Ensuring Early Access to Medicines"
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.7 Articles
7 Articles
(Adnkronos) "The vision of Aifa is to accompany clinical research to the care, an approach that brings added value, because those who do clinical research is a professional in the chain that gives an added value to the patient. We also have to ensure early access to the drug. When the results will be available it is necessary that patients have [...]
The vision of Aifa is to support clinical research with care, an approach that brings added value, because those who do clinical research are a professional in the chain that gives added value to the patient. We also need to ensure early access to the drug. When the results are available it is necessary that patients have [...] L'articolo Rare Diseases, Galliccia (Aifa): "To support research and assistance, to ensure early access to drugs" comes…
Giornale Radio
"Aifa's vision is to support clinical research with care, an approach that brings added value, because clinical research is a professional in the chain that gives added value to the patient. We also need to ensure early access to the drug. When the results are available, patients need to have the benefits with effective medicines."
"Clinical experimentation is a very important element in the treatment of rare diseases." Fabrizio Galliccia, head of the Office, said.
(Adnkronos) - "Clinical experimentation is a very important element in the treatment of rare diseases." Fabrizio Galliccia, director of the Office for Clinical Experiments of the Italian Drug Agency (Aifa), said...
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
